Mr. Thomas Smeenk reports

HEMOSTEMIX PARTNERS WITH MY NEXT HEALTH, OBTAINS USD $150,000 SUBSCRIPTION AT CAD $0.25 PER UNIT, AND INCORPORATES FUNCTIONAL GENOMICS

Hemostemix Inc. has signed a global master services agreement with My Next Health Inc. (MNH) and has, subject to TSX Venture Exchange approval, obtained a subscription from My Next Health in the amount of $150,000 (U.S.) at 25 Canadian cents per unit.

MNH is the world's leading patient-based artificial-intelligence-functional genomic medical analysis company. MNH is improving human health and accelerating the world's transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) and from its comparison of that database to 60 million patient records, MNH has created the world's first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual's health recommendations and clinical trial outcomes. MNH algorithms significantly impact clinical trial subject selection.

Hemostemix will incorporate MNH's functional genomic assays to complete an assay report by individual. Such analyses will enable Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double blind placebo controlled clinical trial.

"We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine," stated Dr. Richard Heinzl, chief executive officer, MNH.

"MNH's tools and analyses enables Hemostemix to explain when, how and why ACP works. These innovations improve the underpinnings of our therapeutics markets, and significantly derisks our clinical trials going forward," stated Thomas Smeenk, chief executive officer.

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company developed and has published seven peer-reviewed articles about the safety and efficacy of its lead product ACP-01 for the treatment of CLI (critical limb ischemia), PAD (peripheral arterial disease), angina, ischemic cardiomyopathy and dilated cardiomyopathy. ACP-01 has been used to treat over 300 patients. ACP-01 is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On Oct. 21, 2019, the company announced the results from its phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.

The company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage and Automated Cell Therapy.

We seek Safe Harbor.